At the time we first started pursuing this litigation, Mounjaro was probably the only label that listed something related to gastroparesis, but it is in no way adequate
Kolodny, L., Horstman, L
PubMed / PMC peer-reviewed research
Incretin-based medications, including GLP-1 receptor agonists like semaglutide (Wegovy) and the dual GIP/GLP-1 receptor agonist tirzepatide (Zepbound), promote weight loss through multiple mechanisms that influence body fat distribution
Tirzepatide is a dual agonist, meaning it activates two hormone pathways: glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1
Individuals with Digestive Disorders : Conditions like Crohns disease, celiac disease, or other gastrointestinal issues can interfere with B12 absorption